GlassScriptPhysician profile
Robert Skotnicki
NPI 1215930334
$1,323.46
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.50 · 2020: $83.94 · 2021: $144 · 2022: $628 · 2023: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $298.65 | 2023 | Ensite Precision |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.31 | 2021-2022 | |
| Boston Scientific Corporation | $139.21 | 2020-2022 | |
| Cvrx, INC. | $111.94 | 2022 | |
| Janssen Pharmaceuticals, INC | $111.74 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.75 | 2022 | |
| Amgen INC. | $96.73 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $73.59 | 2020-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.34 | 2019-2023 | Lifevest |
| Edwards Lifesciences Corporation | $36.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $34.17 | 2023 | |
| Esperion Therapeutics, INC. | $33.82 | 2021 | |
| Merck Sharp & Dohme LLC | $21.68 | 2021 | |
| Pfizer INC. | $18.06 | 2022 | |
| Medtronic, INC. | $15.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Skotnicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.